Chengdu Aoda Biotechnology

Chengdu Aoda Biotechnology is a clinical-stage biopharmaceutical company headquartered in Chengdu, China, specializing in the development of next-generation small molecule therapeutics. The company leverages its proprietary Proteolysis Targeting Chimera (PROTAC) platform to design drugs that degrade disease-causing proteins, particularly in the fields of oncology and metabolic disorders. Its lead candidate, AD-01, is a PROTAC molecule targeting the androgen receptor for the treatment of advanced prostate cancer. Founded in 2017, the company aims to address drug resistance issues associated with traditional protein inhibitors. Aoda Biotechnology has established a comprehensive R&D center in the Chengdu Tianfu International Bio-town to support its growing pipeline.